Cargando…

Bevacizumab for glioblastoma

Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves c...

Descripción completa

Detalles Bibliográficos
Autor principal: Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671800/
https://www.ncbi.nlm.nih.gov/pubmed/26664126
http://dx.doi.org/10.2147/TCRM.S58289
_version_ 1782404456941355008
author Narita, Yoshitaka
author_facet Narita, Yoshitaka
author_sort Narita, Yoshitaka
collection PubMed
description Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed.
format Online
Article
Text
id pubmed-4671800
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46718002015-12-09 Bevacizumab for glioblastoma Narita, Yoshitaka Ther Clin Risk Manag Review Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed. Dove Medical Press 2015-12-01 /pmc/articles/PMC4671800/ /pubmed/26664126 http://dx.doi.org/10.2147/TCRM.S58289 Text en © 2015 Narita. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Narita, Yoshitaka
Bevacizumab for glioblastoma
title Bevacizumab for glioblastoma
title_full Bevacizumab for glioblastoma
title_fullStr Bevacizumab for glioblastoma
title_full_unstemmed Bevacizumab for glioblastoma
title_short Bevacizumab for glioblastoma
title_sort bevacizumab for glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671800/
https://www.ncbi.nlm.nih.gov/pubmed/26664126
http://dx.doi.org/10.2147/TCRM.S58289
work_keys_str_mv AT naritayoshitaka bevacizumabforglioblastoma